Senior Principal Clinical Biomarker Scientist
Current- Biomarker Lead of multiple BMS IO-based clinical trials, including late stage molecules (Nivolumab, Ipilimumab, Relatlimab, IDO1 inhibitor and combination)- Biomarker lead of Repotrectinib (Augtyro) pediatric/young adults ROS1+/NTRK+ solid tumors CARE study- Provides biomarker leadership in MSI-H & MSS Colorectal, Gastric and Pediatric cancer disease strategies - Responsible for developing the biomarker strategy and utilizing emerging diagnostics for the oncology pipeline across all stages of clinical development including regulatory submission - As a pediatric biomarker lead in Pediatric Center of Excellence (PCoE), I am responsible for leading pediatric biomarker strategies for > 20 different solid tumor/ Heme assets in the pipeline across different TRCs/ TM, delivering preclinical biomarker packages to aid iPSP/PIP/ waivers submissions to FDA/EMA. -Responsible for biomarker elements in clinical protocols, biomarker analysis plans, regulatory submissions, investigator meetings, advisory boards and publications- Lead forward and reverse translation research to gain further insights into potential mechanisms of response and resistance to cancer immunotherapy